2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

ESC Scientific Document Group

Research output: Contribution to journalArticlepeer-review

45 Citations (Scopus)
Original languageEnglish
Pages (from-to)4229-4361
Number of pages133
JournalEuropean Heart Journal
Volume43
Issue number41
Early online date26 Aug 2022
DOIs
Publication statusPublished - 1 Nov 2022

Keywords

  • Amyloid light-chain cardiac amyloidosis
  • Androgen deprivation therapy
  • Anthracycline
  • Arrhythmias
  • Atrial fibrillation
  • Biomarkers
  • Cancer
  • Cancer survivors
  • Carcinoid syndrome
  • Cardiac magnetic resonance
  • Cardiac tumour
  • Cardio-oncology
  • Cardiotoxicity
  • Chemotherapy
  • Coronary artery disease
  • Echocardiography
  • Fluoropyrimidine
  • Guidelines
  • Haematopoietic stem cell transplantation
  • Heart failure
  • Hormone therapy
  • Hypertension
  • Immunotherapy
  • Ischaemic heart disease
  • Myocarditis
  • Pericardial disease
  • Proteasome inhibitors
  • Pulmonary hypertension
  • QTc prolongation
  • Radiotherapy
  • Risk stratification
  • Strain
  • Thrombosis
  • Trastuzumab
  • Valvular heart disease
  • Vascular endothelial growth factor inhibitors (VEGFi)
  • Venous thromboembolism

Cite this